Filing Flows

Filing Flows › 8-K events › Evommune

Evommune: entry into a material definitive agreement

Form 8-K filed Nov 4, 2026 · items 1.01, 3.02, 7.01, 8.01

Share offeringsEvommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals

What the filing says

On November 4, 2026, Evommune, Inc. (the “Company”) entered into an Exclusive License Agreement (the “License Agreement”) with Hinova Pharmaceuticals Inc., a company incorporated in the People’s Republic of China (“Hinova”). Pursuant to the License Agreement and subject to certain rights retained by Hinova, Hinova gran

Read the filing on SEC EDGAR →

What usually followsAcross 23,525 8-Ks reporting Item 1.01 (material definitive agreement) in our universe, the stock's median move the next session was 0.0% (typical size ±1.4%, up 51% of the time); over the following 21 sessions, +1.0%. Item 3.02: +0.1% next session across 2,750. Item 8.01: +0.1% next session across 44,881. Every item ranked →

What this kind of filing means

Item 1.01 — Entry into a material definitive agreement. A material agreement is one the company considers important enough to disclose within four business days: a merger agreement, a large supply or customer contract, a credit agreement or a licence. The terms often move the company’s outlook more than a quarter’s results.

Evommune at a glance

Latest quarterQ3 2025
Revenue$10.0M
Operating margin-133.3%
IndustryPharmaceutical Preparations

Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%. The chart follows the revenue to costs, profit and cash.

Evommune: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent share offerings

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.